Clinical Trial News and Research

RSS

Aerovance enrolls 540 patients in Phase 2b Aerovant clinical trial

Aerovance Inc. today announced it has completed patient enrollment in a Phase 2b clinical trial of the inhaled dry powder formulation of Aerovant for the treatment of uncontrolled asthma. Top-line results are expected by the second quarter of 2010.

3 Nov 2009

Health Canada approves the marketing of BioMimetic Therapeutics' Augment Bone Graft

BioMimetic Therapeutics, Inc. announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada.

3 Nov 2009

Exact Sciences announces financial results for the third quarter ended Sept. 30, 2009

Exact Sciences Corp. today announced its financial results for the third quarter ended Sept. 30, 2009.

3 Nov 2009

Arrowhead Research updates its shareholders

Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders.

3 Nov 2009

Puricore reports increase in sales of 25% in Q3

PuriCore, the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today issues an Interim Management Statement covering the three-month and nine-month periods ending September 30, 2009.

3 Nov 2009

NIH awards $4 million research grant to AllTranz

AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company’s transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.

3 Nov 2009

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Seaside Therapeutics LLC today announced that the Company has initiated a Phase 1 clinical trial of STX107, a highly potent, selective mGluR5 antagonist, in development for the treatment of Fragile X Syndrome. The single ascending dose study is designed to evaluate the safety, tolerability and pharmacokinetics of STX107 in healthy volunteers. Fragile X Syndrome is the most common inherited form of mental impairment and the most common known cause of autism.

3 Nov 2009

Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint

Schering-Plough Corporation today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma. The investigational Grass AIT treatment is designed to work by inducing a protective immune response against grass pollen allergy and providing sustained prevention of allergy symptoms, treating both the symptoms and the underlying cause of the disease.

3 Nov 2009

Want to quit smoking? Try a nicotine patch plus a nicotine lozenge

In a comparison of five different smoking cessation medications, a nicotine patch plus a nicotine lozenge appears most effective at helping smokers quit, according to a report in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Nov 2009

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

3 Nov 2009

Crohn's disease drug market driven by TNF-alpha inhibitors Humira and Remicade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira and Remicade, which accounted for more than three-quarters of the market in 2008, will continue to grow through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

3 Nov 2009

Phase 1 study of STX107 for Fragile X syndrome begins

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.

3 Nov 2009

Pregnant women tolerate the 2009 H1N1 flu vaccine, mount strong immune response

Healthy pregnant women mount a robust immune response following just one dose of 2009 H1N1 influenza vaccine, according to initial results from an ongoing clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

3 Nov 2009

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

ARIAD Pharmaceuticals, Inc. today announced that the scientific journal, Cancer Cell, has published a comprehensive paper describing the design and preclinical characterization of AP24534, ARIAD’s investigational, multi-targeted kinase inhibitor.

3 Nov 2009

NIA funds national Testosterone Trial, Penn Medicine to lead

Penn Medicine will lead a new national $45 million clinical trial to test whether testosterone therapy can favorably affect certain conditions affecting older men. Low serum testosterone may contribute to a number of problems affecting older men, including decreased ability to walk, loss of muscle mass and strength, decreased vitality, decreased sexual function, impaired cognition, cardiovascular disease and anemia. While testosterone normally decreases with age, in some men, low levels of testosterone may contribute to these debilitating conditions.

2 Nov 2009

Malaria conference begins in Nairobi, will highlight outlook for RTS,S experimental malaria vaccine

The 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference "kicked off in Nairobi late Sunday with a call for substantial and sustained support for research to guide evidence-based policies and the development of new malaria tools, which together could save countless lives," Xinhua reports (11/2).

2 Nov 2009

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has commenced a randomized, double-blind, placebo-controlled Pilot Study of up to 165 persons who have type 2 diabetes, the most common form of diabetes.

2 Nov 2009

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Enzo Biochem Inc. announced today that favorable results of the Company’s clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo’s orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.

2 Nov 2009

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

Gilead Sciences, Inc., in collaboration with GlaxoSmithKline (GSK), today announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH).

2 Nov 2009

EnzymeRx commences patient enrollment in Uricase-PEG 20 phase 1 study

EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.

2 Nov 2009

Clinical Trial News and Research

Aerovance enrolls 540 patients in Phase 2b Aerovant clinical trial

Health Canada approves the marketing of BioMimetic Therapeutics' Augment Bone Graft

Exact Sciences announces financial results for the third quarter ended Sept. 30, 2009

Arrowhead Research updates its shareholders

Puricore reports increase in sales of 25% in Q3

NIH awards $4 million research grant to AllTranz

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint

Want to quit smoking? Try a nicotine patch plus a nicotine lozenge

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Crohn's disease drug market driven by TNF-alpha inhibitors Humira and Remicade

Phase 1 study of STX107 for Fragile X syndrome begins

Pregnant women tolerate the 2009 H1N1 flu vaccine, mount strong immune response

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

NIA funds national Testosterone Trial, Penn Medicine to lead

Malaria conference begins in Nairobi, will highlight outlook for RTS,S experimental malaria vaccine

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

EnzymeRx commences patient enrollment in Uricase-PEG 20 phase 1 study

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News